FDA
-
-
-
-
-
-
-
Prometic reports its 2019 first quarter financial results
-
-
-
-
-
-
-
Prometic Reports Second Quarter 2018 Financial Results and Highlights
-
-
-
-
-
-
-
Prometic receives Rare Pediatric Disease Designation from U.S. FDA for its Inter-Alpha-Inhibitor-Proteins
-
-
-
-
-
-
-
Pivotal Data for Prometic's Intravenous Plasminogen Replacement Therapy to Be Presented at American Society for Hematology
-
-
-
-
-
-
-
Prometic Receives Rare Pediatric Disease Designation From U.S. FDA for its Plasminogen Replacement Therapy
-
-
-
-
324,764 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

